Elizabeth Halloran
Director
Expertise:
As a director on the Value & Evidence team at EVERSANA®, Elizabeth leads evidence synthesis projects involving systematic literature reviews and indirect treatment comparisons, supporting reimbursement and market access of pharmaceutical products.
Elizabeth specializes in the conduct and critical appraisal of evidence synthesis activities. Since joining the team in 2018, she has co-authored several conference abstracts and posters, in addition to peer-reviewed publications of systematic reviews and indirect treatment comparisons. She has also supported the submissions of new products to various health technology assessment agencies. Her work has spanned several therapeutic areas including multiple sclerosis, breast cancer, and prostate cancer. Elizabeth has also managed AI-assisted literature review projects and co-authored congress presentations focused on this developing area.
Prior to joining EVERSANA, Elizabeth pursued scientific research focused on the development and validation of point-of-care diagnostic devices designed for immunological and bacterial disease detection. Elizabeth’s academic training includes an Honours B.Sc. in Chemical Biology with a minor in Biology, as well as a M.Sc. in Chemical Biology from McMaster University.
Articles by Elizabeth Halloran
Comparing Long-Term HAE Treatments: Insights from a Robust Network Meta-Analysis
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent edema attacks in various parts of the body, including the extremities, face, gastrointestinal tract, and airway. While most current treatments can help relieve acute symptoms pf HAE, long-term prophylactic treatment plays a critical role in minimizing attack frequency and improving quality of life. Current […]
New Insights into Brain Volume Loss in MS
We are excited to announce that members of the EVERSANA team have contributed to a significant publication in BMC Neurology. The study, titled “Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies,” provides valuable insights into the effects of various treatments on brain volume loss (BVL) in patients with relapsing […]